AlphaRose Therapeutics Secured NIH Funding for Rare Disease
The firm received an SBIR Fast Track grant to advance an antisense oligonucleotide treatment for Bain Syndrome.
Updated on Sept. 29, 2026 in Biotech
Live Poll
Do you support increasing government funding for private firms developing AI-based treatments for rare diseases?
AlphaRose Therapeutics has been awarded an NIH Small Business Innovation Research grant to support the development of Rosiphersen. This antisense oligonucleotide therapy targets Bain Syndrome, a severe pediatric neuro-developmental disease linked to HNRNPH2 gene variants.
Why it matters
The funding aims to accelerate the clinical development of Rosiphersen toward an Investigational New Drug application. This represents a significant push to address a condition that currently has no established cure.
AlphaRose utilizes an AI drug design operating system, RINAE.AI, to develop therapeutic candidates. The platform focuses on engineering antisense oligonucleotides, which are short strands of synthetic DNA or RNA that modulate gene expression.
The players
AlphaRose Therapeutics
A biotechnology firm utilizing the RINAE.AI platform for the computational design of antisense oligonucleotide drug candidates.
National Institute of Health
The primary federal agency responsible for biomedical and public health research in the United States.
The details
The grant supports the progression of Rosiphersen, an antisense oligonucleotide — a synthetic molecule designed to bind to messenger RNA to alter protein production. The company uses its proprietary RINAE.AI platform to design these candidates specifically to address HNRNPH2 gene variants. This approach seeks to modulate the genetic expression underlying Bain Syndrome, which currently lacks any disease-modifying treatment.
Timeline
September 29, 2026: AlphaRose Therapeutics received the NIH SBIR grant.
End of 2027: The company plans to reach first-in-human safety data milestones.
The Tech Race
The National Institute of Health's SBIR grant program provides a vital funding mechanism for early-stage biotechnology firms to de-risk high-barrier rare disease research. This award follows the standard path of the program, which provides federal support to bridge the gap between academic research and commercial clinical trials.
This development marks a research-stage milestone rather than a clinical-ready product for patients. The progress of this therapy remains dependent on the success of the upcoming Investigational New Drug application process.
The takeaway
The trajectory of this therapy depends on the company's ability to successfully leverage its RINAE.AI platform to move Rosiphersen through regulatory hurdles. Stakeholders should monitor for the filing of an Investigational New Drug application ahead of the 2027 safety data target.
What happens next
AlphaRose Therapeutics is targeting the delivery of first-in-human safety data by the end of 2027.
Further reading
For more on the current landscape of genetic therapies, see our Biotech section.
Source note: This article includes information reported by Scientist Live.
Live Poll
Do you support increasing government funding for private firms developing AI-based treatments for rare diseases?
